The Impact of Persistent Irritability on the Medication Treatment of Paediatric Attention Deficit Hyperactivity Disorder
- PMID: 34366928
- PMCID: PMC8333707
- DOI: 10.3389/fpsyt.2021.699687
The Impact of Persistent Irritability on the Medication Treatment of Paediatric Attention Deficit Hyperactivity Disorder
Abstract
This study compares the efficacy and tolerability of central nervous system (CNS) stimulants in children with attention deficit hyperactivity disorder (ADHD) with and without prominent irritability (IRR) over the course of 30 months. This is a secondary analysis of a study examining growth patterns in medication naïve children with ADHD subsequently treated with CNS stimulants (predominantly OROS-Methylphenidate, up to 54 mg per day) for 30 months. Participants had to meet full diagnostic criteria for ADHD and been treated with CNS stimulants for under 30 days. Children were classified as IRR if they were rated as pretty much or very much on either of the "often angry" or easily annoyed" items plus "lose temper," items of the Disruptive Behavior Disorders Rating Scale (DBDRS). Structured ratings of ADHD symptoms, impairment, side effects, and symptoms of oppositional defiant disorder (ODD) were collected every 2-12 weeks for the duration of the study. Medication use was measured by pill count and parent report. The IRR group comprised 28% of all participants. The IRR group had significantly higher levels of ADHD and ODD symptoms, impairment, and side effects ratings at baseline. In the IRR group, ODD symptoms, emotional lability, and impairment significantly decreased for participants with higher medication use. Total side effects increased for non-IRR participants with higher medication use. Emotional side effects decreased for IRR participants with higher medication use. Central nervous system stimulants were a tolerable and efficacious treatment in treatment naïve youth with ADHD with irritability. Clinical Trials Registration: NCT01109849.
Keywords: ADHD; CNS stimulant; children; irritability; medication.
Copyright © 2021 Baweja, Waschbusch, Pelham, Pelham and Waxmonsky.
Conflict of interest statement
JW has received research funding from the National Institutes of Health, Supernus, and Pfizer in the past 3 years. WP (4th author) has received funding from NIMH, NIAAA, NIDA, and the Institute of Education Sciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Improvements in Irritability with Open-Label Methylphenidate Treatment in Youth with Comorbid Attention Deficit/Hyperactivity Disorder and Disruptive Mood Dysregulation Disorder.J Child Adolesc Psychopharmacol. 2018 Jun;28(5):298-305. doi: 10.1089/cap.2017.0124. Epub 2018 Apr 30. J Child Adolesc Psychopharmacol. 2018. PMID: 29708762 Free PMC article.
-
Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.J Child Adolesc Psychopharmacol. 2016 May;26(4):362-71. doi: 10.1089/cap.2015.0031. Epub 2016 Jan 18. J Child Adolesc Psychopharmacol. 2016. PMID: 26779845 Clinical Trial.
-
Changes in Sleep Problems Across Attention-Deficit/Hyperactivity Disorder Treatment: Findings from the Multimodal Treatment of Attention-Deficit/Hyperactivity Disorder Study.J Child Adolesc Psychopharmacol. 2018 Dec;28(10):690-698. doi: 10.1089/cap.2018.0038. Epub 2018 Nov 2. J Child Adolesc Psychopharmacol. 2018. PMID: 30388029 Free PMC article. Clinical Trial.
-
The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.Clin Ther. 2009 Jan;31(1):142-76. doi: 10.1016/j.clinthera.2009.01.015. Clin Ther. 2009. PMID: 19243715 Review.
-
A Mini-Review of Pharmacological and Psychosocial Interventions for Reducing Irritability Among Youth With ADHD.Front Psychiatry. 2022 Feb 14;13:794044. doi: 10.3389/fpsyt.2022.794044. eCollection 2022. Front Psychiatry. 2022. PMID: 35237188 Free PMC article. Review.
Cited by
-
A Post-Hoc Analysis of Emotional Lability With Delayed-Release/Extended-Release Methylphenidate in Children Aged 6 to 12 Years of Age Participating in Two Phase 3 Clinical Trials.J Atten Disord. 2024 Jun;28(8):1186-1197. doi: 10.1177/10870547241243155. Epub 2024 Apr 10. J Atten Disord. 2024. PMID: 38600754 Free PMC article. Clinical Trial.
-
History of Childhood/Adolescence Referral to Speciality Care or Treatment in Adult Patients with Attention-Deficit/Hyperactivity Disorder: Mutual Relations with Clinical Presentation, Psychiatric Comorbidity and Emotional Dysregulation.Brain Sci. 2023 Aug 27;13(9):1251. doi: 10.3390/brainsci13091251. Brain Sci. 2023. PMID: 37759852 Free PMC article.
-
Treatment Utilization Pattern of Preschool Children With Attention-Deficit/Hyperactivity Disorder.J Atten Disord. 2024 Mar;28(5):708-721. doi: 10.1177/10870547231215287. Epub 2023 Dec 12. J Atten Disord. 2024. PMID: 38084067 Free PMC article.
-
Drug Holidays May Attenuate Beneficial Effects of Treatment on Emotion Regulation and Recognition Among Children with ADHD: A Single-Center, Prospective Study.Psychiatry Clin Psychopharmacol. 2024 Nov 28;34(4):285-293. doi: 10.5152/pcp.2024.24862. Psychiatry Clin Psychopharmacol. 2024. PMID: 39629771 Free PMC article.
References
-
- American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, 5th ed. Washington, DC: American Psychiatric Press; (2013).
-
- Ezpeleta L, Granero R, de la Osa N, Trepat E, Domènech JM. Trajectories of oppositional defiant disorder irritability symptoms in preschool children. J Abnorm Child Psychol. (2016) 44:115–28. 10.1007/s10802-015-9972-3 - PubMed
Associated data
LinkOut - more resources
Full Text Sources
Medical